1-(3-(4-acetyl-1,4-diazepan-1-yl)phenyl)guanidine | 1421693-19-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(3-(4-acetyl-1,4-diazepan-1-yl)phenyl)guanidine
• CAS: 1421693-19-7
• 化学式: C₁₄H₂₁N₅O
• 分子量: 275.354
• InChiKey: QJPBWZLQAKQWLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.05
• 重原子数：
  20.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  85.45
• 氢给体数：
  3.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-(dimethylamino)-2-methyl-1-(4-methyl-2-(methylamino)thiazol-5-yl)prop-2-en-1-one 、 1-(3-(4-acetyl-1,4-diazepan-1-yl)phenyl)guanidine 以 乙二醇甲醚 为溶剂， 以3%的产率得到(methyl-((((2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)phenyl)-1,4-diazepan-1-yl)ethanone
  参考文献：
  名称：

  Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113244

文献信息

• Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations
  作者：Yi Long、Mingfeng Yu、Aleksandra M. Ochnik、Jasmine D. Karanjia、Sunita KC. Basnet、Alemwork A. Kebede、Lianmeng Kou、Shudong Wang

  DOI：10.1016/j.ejmech.2021.113215

  日期：2021.3

  tyrosine kinase 3 (FLT3) is one of the most pursued targets in the treatment of acute myeloid leukaemia (AML) as its gene amplification and mutations, particularly internal tandem duplication (ITD), contribute to the pathogenesis of AML and the resistance to known FLT3 inhibitors. To conquer this challenge, there is a quest for structurally novel FLT3 inhibitors. Herein, we report the discovery of a new series

  猫McDonough肉瘤（FMS）样酪氨酸激酶3（FLT3）是急性髓细胞白血病（AML）的治疗中最受关注的靶标之一，因为其基因扩增和突变，尤其是内部串联重复（ITD）有助于发病AML和对已知FLT3抑制剂的耐药性。为了克服这一挑战，寻求结构新颖的FLT3抑制剂。在这里，我们报告发现了一系列新的4-氮杂芳基-N-苯基嘧啶-2-胺衍生物作为有效的和选择性的FLT3抑制剂。化合物12b和12r能够抑制各种突变的FLT3激酶，包括ITD和D835Y突变体；后者同工型与获得性耐药密切相关。此外，这两种化合物显示抗增殖特异性FLT3 -ITD-窝藏细胞系（我。Ë在那些与野生型激酶或即使没有FLT3表达的表达。，MV4-11和MOLM-13细胞）。在使用MV4-11细胞的机制研究中，发现12b可以减少FLT3关键下游效应子的磷酸化并诱导凋亡，从而支持FLT3-ITD靶向的抗增殖作用机制。
• Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities
  作者：Hao Shao、Shenhua Shi、Shiliang Huang、Alison J. Hole、Abdullahi Y. Abbas、Sonja Baumli、Xiangrui Liu、Frankie Lam、David W. Foley、Peter M. Fischer、Martin Noble、Jane A. Endicott、Chris Pepper、Shudong Wang

  DOI：10.1021/jm301475f

  日期：2013.2.14

  Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the CS-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,(34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B-and T-cells.